WO2001010378A2 - Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations - Google Patents
Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations Download PDFInfo
- Publication number
- WO2001010378A2 WO2001010378A2 PCT/BR2000/000086 BR0000086W WO0110378A2 WO 2001010378 A2 WO2001010378 A2 WO 2001010378A2 BR 0000086 W BR0000086 W BR 0000086W WO 0110378 A2 WO0110378 A2 WO 0110378A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- methacrylic acid
- methyldopa
- dopa
- acrylic acid
- Prior art date
Links
- 229920001577 copolymer Polymers 0.000 title claims abstract description 54
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960004205 carbidopa Drugs 0.000 title claims abstract description 34
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title claims abstract description 34
- 238000013270 controlled release Methods 0.000 title claims abstract description 23
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 title claims description 53
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 title description 28
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 title description 5
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 claims abstract description 84
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 51
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 35
- 238000006243 chemical reaction Methods 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000003054 catalyst Substances 0.000 claims abstract description 8
- 230000008569 process Effects 0.000 claims abstract description 8
- 238000005660 chlorination reaction Methods 0.000 claims abstract description 7
- 238000001035 drying Methods 0.000 claims abstract description 6
- 230000001079 digestive effect Effects 0.000 claims abstract description 4
- 239000003960 organic solvent Substances 0.000 claims abstract description 4
- 238000005406 washing Methods 0.000 claims abstract description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 35
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000005395 methacrylic acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 34
- -1 poly(acrylic acid) Polymers 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 238000012377 drug delivery Methods 0.000 abstract description 7
- 230000002939 deleterious effect Effects 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 description 26
- 239000000203 mixture Substances 0.000 description 20
- 239000003826 tablet Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 9
- 230000009102 absorption Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000006069 physical mixture Substances 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 229960004502 levodopa Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 150000008064 anhydrides Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000227 bioadhesive Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003954 decarboxylase inhibitor Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 238000004483 ATR-FTIR spectroscopy Methods 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940052036 carbidopa / levodopa Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 239000011557 critical solution Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012430 organic reaction media Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to pharmaceutical preparations for the controlled release of L- ⁇ -methyldopa or L-dopa optionally associated with carbidopa aiming to minimize the adverse reactions and inadequacies often experienced with the administration of commonly used dosage of these known antihypertensive and anti-Parkinsonism agents, respectively.
- the pharmaceutical preparations are based on new copolymers of acrylic or methacrylic acid/L- ⁇ -methyldopa, acrylic or methacrylic acid/ L-dopa and acrylic or methacrylic acid/carbidopa having enhanced adhesion to the gastric mucous membrane which permits a substantial intake medicine reduction.
- Poly (acrylic acid) is the preferential polymer used to obtain the copolymers of the present invention.
- L-dopa (3-hydroxy-L-tyrosine; 3, -dihydroxy-L- phenylalanine) the immediate biological precursor of dopamine, is a known compound and the most commonly used drug in the therapeutic treatment of Parkinsonism.
- L-dopa levodopa
- SinemetTM trade name for levodopa
- L- ⁇ -methyldopa the L form of ⁇ -methyl- ⁇ - (3, 4- dihydroxyphenyl) alanine, is an analogue of levodopa and an important drug in the therapeutic treatment of hypertension.
- L-dopa and ⁇ - methyldopa formulations using drug carriers capable of delaying the drug release in the body were developed.
- Conventional dosage forms, including prolonged-release dosage forms, are based on physical mixtures containing one or more drugs and a carrier, frequently a polymeric material which may be natural as well as partially or totally synthetic polymer.
- US Patent 4,424,235 describes hydrodynamically balanced controlled release compositions for the preparation of capsules or tablets containing L-dopa and a decarboxylase inhibitor.
- ⁇ -Methyldopa is cited as a decarboxylase inhibitor used in the composition which includes natural as well as partially or totally synthetic hydrocolloids such as guar gum, agar, pectin, carrageen, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, gelatin, etc to provide superior blood levels of L-dopa.
- Document EP 320 051 describes a controlled release combination of carbidopa/levodopa which is a matrix or monolithic drug delivery system consisting of two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer.
- the polymers cited in this document belong to the group of water soluble polymers and less water soluble polymers, preferentially a combination of these types, such as hydroxypropylcellulose and poly (vinyl acetate/crotonic acid).
- DDS new drug delivery systems
- DDS forms such as drug complexed to a polymeric membrane or formed as a molded product to be adhered on skin or a mucous membrane for slow release or absorption of the drug through the skin or the mucous membrane, respectively; body implant systems in which a drug complexed to various forms of matrix is left in an organ or subcutaneous tissues for slow release; systems in which the drug is microencapsulated by means of liposome or lipid microspheres or as a prodrug formed by covalently bonding a drug to a polymeric compound which is administered directly in the blood or tissues.
- Prodrugs i.e. drugs that are chemically linked to a polymer
- a drug carrier comprising a temperature-sensitive polymeric compound chemically bound to a drug having lower LCST (Lower Critical Solution Temperature) than the body temperature attempting to achieve an enhancement of administration ease and uniform drug concentration for a long period of time in the tissues.
- Anti-cancer agents, hormones, antibiotics, narcotic antagonists, analgesics, anti-inflamatory agents, hypotensives, anti-depressants, anti-epileptic agents, anti- malarial agents, anti-helmintics or immunoactivators are cited as drugs to be combined with the drug carrier.
- EP 452 179 refers to a compound combined with a medicine and a polymer having an alkylenoxy group, such as polyethylene glycol, the combination having directional characteristics to digestive organs.
- WO 90/15628 describes a polymer/antibiotic conjugate in which the polymer is conjugated to the antibiotic via a covalent bond to get a greater therapeutic index as compared with that of the free antibiotic but maintaining the same activity of the latter.
- the object of the invention is to provide a site directed drug delivery system providing a controlled release of L-dopa, carbidopa and/or their combinations and L- ⁇ - methyldopa which eliminates or at least reduces the deleterious side effects of these drugs.
- a first embodiment of the present invention refers to a copolymer of acrylic or methacrylic acid/ L- ⁇ -methyldopa.
- the invention is directed to a copolymer of acrylic or methacrylic acid/ L-dopa.
- the invention is directed to a copolymer of acrylic or methacrylic acid/ carbidopa.
- a fourth embodiment is related with pharmaceutical compositions based on a copolymer of acrylic or methacrylic acid/ L-dopa, on a copolymer of acrylic or methacrylic acid/carbidopa and on their combinations.
- a fifth embodiment is related with pharmaceutical compositions based on a copolymer of acrylic acid/L- ⁇ - methyldopa, on a copolymer of methacrylic acid/L- ⁇ -methyldopa and on their combinations.
- the invention is directed to a process for the production of biologically active copolymers of acrylic or methacrylic acid/L-dopa, acrylic or methacrylic acid/carbidopa and acrylic acid/L- ⁇ -methyldopa having directional characteristics to the digestive mucous tissue comprising the steps of:
- step (b) bringing into reaction the product of step (a) and poly (acrylic acid) or poly (methacrylic acid) in the presence of a suitable catalyst;
- step (c) washing the copolymer obtained in step (b) with a suitable organic solvent and drying it until constant weight.
- FIGURE 1 illustrates a calibration curve to evaluate the conversion degree of L- ⁇ -methyldopa.
- FIGURE 2 shows the infrared spectrum of L- ⁇ -methyldopa.
- FIGURE 3 shows the infrared spectrum of poly (acrylic acid) .
- FIGURE 4 shows the infrared spectrum of copolymer acrylic acid/L- ⁇ -methyldopa of the present invention.
- FIGURE 5 shows the NMR spectrum of L- ⁇ -methyldopa.
- FIGURE 6 shows the NMR spectrum of poly (acrylic acid).
- FIGURE 7 shows the NMR spectrum of copolymer acrylic acid/L- ⁇ -methyldopa of the present invention.
- FIGURE 8 illustrates a calibration curve of release kinectics to evaluate the release degree of L- ⁇ -methyldopa.
- FIGURE 9 shows graphically the L- ⁇ -methyldopa release from a tablet based on the copolymer acrylic acid/L- ⁇ - methyldopa of the present invention.
- FIGURE 10 shows graphically the L- ⁇ -methyldopa release from a tablet based on a mixture of poly (acrylic acid) and L- ⁇ -methyldopa .
- FIGURE 11 illustrates graphically the comparison between the L- ⁇ -methyldopa release rates from tablets based on the physical mixture of poly (acrylic acid) and L- ⁇ -methyldopa and that from tablets based on the copolymer acrylic acid/L- ⁇ - methyldopa of the present invention (%/hour).
- FIGURE 12 illustrates graphically the comparison between the L- ⁇ -methyldopa release rates from tablets based on the physical mixture of poly (acrylic acid) and L- ⁇ -methyldopa and that from tablets based on the copolymer acrylic acid/L- ⁇ - methyldopa of the present invention (mg/hour) .
- L- ⁇ -methyldopa was introduced in the market in 1962 in Germany by Merck & Co with the trade name Aldomet . Since then, L- ⁇ -methyldopa has been frequently prescribed for individuals suffering from moderate to severe hypertension and depending on the severity of the hypertension (high blood pressure) the daily dosage may range from 0.5 to 3.0 g. The drug effect occurs after 3 to 6 hours from the administration and remains for 24 to 48 hours. The L- ⁇ -methyldopa absorption is variable and incomplete. Only about 50% of the oral dose is absorbed by the organism and its elimination half-life is 1.7 hours .
- this is accomplished by providing a copolymer obtained by reacting L-dopa, carbidopa or L- ⁇ -methyldopa with a mucoadhesive polymer, such as poly (acrylic acid) or poly (methacrylic acid).
- a mucoadhesive polymer such as poly (acrylic acid) or poly (methacrylic acid).
- Mucoadhesion may be defined as the ability of a material to adhere to a mucous tissue for an extended period of time.
- the mucus is the layer covering the mucosa aiming its protection against mechanical, chemical, microbiological and viral aggressions. Besides its gastric protection role against back diffusion of hydrochloric acid, the mucus provides a diffusion barrier for molecules, and especially against drug absorption. In fact, diffusion through the mucus layer depends largely on the active ingredients physicochemical characteristics and their intimate contact. Smart et al . (Smart, J.D., Kellaway, I.W.
- the values in Table 1 were obtained by following the methology described by Smart et al .
- the choise of an appropriate polymer to be used in controlled release pharmaceutical preparations must take into account several physicochemical properties of the adhesion site.
- Studies using fluorescence methods (Hui, Ho-Wah, Robinson, J.R. 1985, "Ocular delivery of progesterone using a bioadhesive polymer", International Journal of Pharmaceutics, 26:203-213) showed that (i) cationic and anionic polymers have higher adhesiveness than neutral polymers; (ii) referring to the relation adhesiveness :potential toxicity, polyanions have a better performance than polycations; (iii) the presence of sulfate groups in polymers provide an enhanced adhesiveness as compared with polymers having carboxylic groups; (iv) the adhesive strength is proportional to the charge density of the polymer.
- bioadhesive polymers are recommended for (a) drug controlled release; (b) active substances directed to absorption in specific sites; (c) increasing the medicine residence time into the body and (d) prodrugs .
- the polymers poly (acrylic acid) (PAA) and poly (methacrylic acid) (PMAA) used in the present invention have a Molecular Weight up to 200,000 and were formed by polymerizing acrylic or methacrylic acid using standard techniques. In a preferred manner, the polymers were prepared from acrylic acid or from methacrylic acid in an aqueous medium.
- L-dopa, carbidopa or L- ⁇ -methyldopa and a chlorination agent, e.g. tionyl chloride are brought into reaction at a temperature of up to 10°C and under positive pressure of inert gas, such as nitrogen, to avoid hydrolysis of the acid chloride recently formed and to improve reaction yield by stripping off side products such as S0 2 and HCl in a system provided with a neutralization device.
- the copolymer is obtained by the addition of poly (acrylic acid) or poly (methacrylic acid) to the reaction medium and is preferentially carried out in the presence of a suitable catalyst at a temperature of up to 20°C. Pyridine or its derivatives are preferred catalysts due to their low nucleophilic strength and good solubility in the organic reaction medium.
- the reaction conditions facilitate the formation of the copolymer in its anhydride form. Indeed, the excess of the chlorination agent endeavorees the formation of L- ⁇ -methyldopa (or L-dopa or carbidopa) chloride and, consequently, the highly acidic medium leads to a protonic form of the amine group of the L- ⁇ -methyldopa (or L-dopa or carbidopa) , inhibiting amide formation which could result from the reaction between L- ⁇ -methyldopa (or L-dopa or carbidopa) with PAA (or poly (methacrylic acid)) or with another molecule of L- ⁇ -methyldopa (or L-dopa or carbidopa) .
- PAA poly (methacrylic acid)
- reaction characteristics are: excess of chlorination agent which permits the elimination of humidity from PAA or from poly (methacrylic acid); presence of a catalyst which activates the reactant L- ⁇ -methyldopa (or L-dopa or carbidopa) chloride and low reaction temperature inhibiting the formation of anhydride cross linkages in the copolymer.
- the reaction yield was high, i.e. the reaction occured with a high conversion degree.
- the resulting copolymers acrylic or methacrylic acid/L- ⁇ -methyldopa, acrylic or methacrylic acid/L-dopa and acrylic or methacrylic acid/carbidopa are then purified by using standard techniques to remove side products, non-reacted reactants, catalyst and reaction solvent.
- the final step of the purification process is the dispersion of the obtained product in a suitable medium, e.g. tetrahydrofuran, followed by a filtration step under vacuum and a drying step.
- an effective amount of the copolymers of the present invention may be incorporated into a pharmaceutical composition preferably for oral administration.
- suitable forms of solid oral dosage are tablets, troches, capsules and the like.
- common pharmaceutically acceptable compounding ingredients i.e. diluents, flavorings, stabilizers, tabletting lubricants, preservatives, coloring agents and the like may be used.
- the amount of the inert pharmaceutical adjunct materials which may be present in the controlled release formulations of the invention will vary in accordance with the amounts and physical properties of the other components. Such conventional pharmaceuticals adjuncts are present in from about 5% to about 60% by weight of the formulation.
- the reaction of the acrylic acid with L- ⁇ -methyldopa is similar to the reactions of the acrylic acid with L-dopa and of the acrylic acid with carbidopa.
- the homology between methacrylic acid and acrylic acid also facilitates the reactions of methacrylic acid with L- ⁇ -methyldopa, methacrylic acid with L-dopa and methacrylic acid with carbidopa.
- the resultant polymer was purified by dissolving the chips in a 10% methanol solution.
- the product was recovered after precipitation by using ethyl ether, the precipitation step being repeated for three times.
- the temperature was then increased to 11°C and 7.206 g (0.1 mol) of dry poly (acrylic acid) obtained according to Example 1, was added and the reaction was allowed to proceed for 24 hours. During the copolymer formation, the reaction was monitored by thin layer chromatography .
- the average conversion degree as calculated from the values in the last column of Table 2 is 50.60%.
- An additional purification step was carried out by grinding the copolymer, washing two times with dioxane and drying it until constant weight.
- the final product is white; hygroscopic; soluble in water, absolute ethanol, acetone and dimethyl formamide; insoluble in tetrahydrofuran, dioxane, ethyl ether and ethyl acetate; has a lower T g (Glass Transition Temperature) as compared to PAA and has high adhesiveness to human skin.
- the structure of the copolymers of the present invention were characterized by using infrared spectroscopy and C 13 NMR (nuclear magnetic resonance) techniques. Likewise, PAA and L- ⁇ -methyldopa were characterized for comparison purposes.
- Figures 2, 3 and 4 show the infrared spectra of L- ⁇ - methyldopa, of PAA and of copolymer acrylic acid/ L- ⁇ - methyldopa, respectively.
- Figures 5, 6 and 7 show the C 13 NMR spectra of L- ⁇ - methyldopa, of PAA and of copolymer acrylic acid/ L- ⁇ - methyldopa, respectively.
- Formulation of pharmaceutical tablets based on the copolymer acrylic acid/methyldopa (PAA-mDOPA) of the present invention 14.908 g of PAA-mDOPA, 0.3 g of magnesium stearate, 0.3 g of silicium dioxide and 0.451 g of mannitol were mixed and ground to obtain a fine and homogeneous powdered mixture. Tablets were prepared by compressing this mixture using known techniques .
- the formulation was made to obtain tablets with a total weight of 800 mg in which 400 mg of L- ⁇ - methyldopa are included.
- the characteristics of this preparation are shown in Table 3.
- Example 4 tablets based on physical mixture of linear poly (acrylic acid) and L- ⁇ - methyldopa were prepared.
- the formulation was prepared so as to obtain tablets with a total weight of 800 mg in WO 01/10378 2 ⁇ PCT/BROO/00086
- Table 4 Tablets based on a physical mixture of PAA and L- ⁇ - methyldopa
- the release values in Tables 3 and 4 may be used to determine the average percent release of L- ⁇ -methyldopa.
- Table 6 shows the results obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0111066A GB2384426A (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-α-Methyl dopa, acrylic or methacrylic |
AU61426/00A AU6142600A (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-alpha-methyl dopa, acrylic or methacrylic acid/carbidopaand their combinations |
EP00947704A EP1117370A1 (en) | 1999-08-04 | 2000-08-02 | CONTROLLED RELEASE FROM COPOLYMERS OF ACRYLIC OR METHACRYLIC ACID/L-DOPA, ACRYLIC OR METHACRYLIC ACID/L-$g(a)-METHYL DOPA, ACRYLIC OR METHACRYLIC ACID/CARBIDOPA AND THEIR COMBINATIONS |
DE10082749T DE10082749T1 (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid / L-dopa, acrylic or methacrylic acid / L-a-methyldopa, acrylic or methacrylic acid / carbidopa and their combinations |
CA002346291A CA2346291A1 (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-.alpha.-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9903382-8A BR9903382A (en) | 1999-08-04 | 1999-08-04 | Copolymers of acrylic or methacrylic acid / l-dopa, acrylic or methacrylic acid / l- <244> methyldopa or acrylic or methacrylic acid / l-carbidopa, process of obtaining it and drug compositions containing the same |
BRPI9903382-8 | 1999-08-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001010378A2 true WO2001010378A2 (en) | 2001-02-15 |
WO2001010378A3 WO2001010378A3 (en) | 2001-08-30 |
Family
ID=4073069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2000/000086 WO2001010378A2 (en) | 1999-08-04 | 2000-08-02 | Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1117370A1 (en) |
AU (1) | AU6142600A (en) |
BR (1) | BR9903382A (en) |
CA (1) | CA2346291A1 (en) |
DE (1) | DE10082749T1 (en) |
GB (1) | GB2384426A (en) |
WO (1) | WO2001010378A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005056708A2 (en) * | 2003-12-09 | 2005-06-23 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
WO2006026556A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Bioadhesive rate-controlled oral dosage formulations |
WO2006039022A2 (en) * | 2004-08-27 | 2006-04-13 | Spherics, Inc. | Controlled regional oral delivery |
WO2007002318A2 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Bioadhesive polymers |
WO2024078607A1 (en) * | 2022-10-14 | 2024-04-18 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method therefor |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2324810B1 (en) | 2009-11-19 | 2014-10-29 | Ivoclar Vivadent AG | Filled dental material based on polymerisable dihydroxyphenylalanine derivatives |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0359996A2 (en) * | 1988-08-22 | 1990-03-28 | Al Marzook United Commercial Co. | Synthetic amino acid-and/or peptide-containing graft copolymers |
EP0506979A1 (en) * | 1990-10-24 | 1992-10-07 | Eisai Co., Ltd. | Organic polymer compound and production thereof |
-
1999
- 1999-08-04 BR BR9903382-8A patent/BR9903382A/en unknown
-
2000
- 2000-08-02 WO PCT/BR2000/000086 patent/WO2001010378A2/en not_active Application Discontinuation
- 2000-08-02 DE DE10082749T patent/DE10082749T1/en not_active Withdrawn
- 2000-08-02 AU AU61426/00A patent/AU6142600A/en not_active Abandoned
- 2000-08-02 GB GB0111066A patent/GB2384426A/en not_active Withdrawn
- 2000-08-02 EP EP00947704A patent/EP1117370A1/en not_active Withdrawn
- 2000-08-02 CA CA002346291A patent/CA2346291A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0359996A2 (en) * | 1988-08-22 | 1990-03-28 | Al Marzook United Commercial Co. | Synthetic amino acid-and/or peptide-containing graft copolymers |
EP0506979A1 (en) * | 1990-10-24 | 1992-10-07 | Eisai Co., Ltd. | Organic polymer compound and production thereof |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005056708A2 (en) * | 2003-12-09 | 2005-06-23 | Spherics, Inc. | Bioadhesive polymers with catechol functionality |
WO2005056708A3 (en) * | 2003-12-09 | 2005-07-28 | Spherics Inc | Bioadhesive polymers with catechol functionality |
JP2007517776A (en) * | 2003-12-09 | 2007-07-05 | スフェリックス, インコーポレイテッド | Bioadhesive polymers with catechol functional groups |
WO2006039022A3 (en) * | 2004-08-27 | 2006-08-10 | Spherics Inc | Controlled regional oral delivery |
WO2006039022A2 (en) * | 2004-08-27 | 2006-04-13 | Spherics, Inc. | Controlled regional oral delivery |
WO2006026504A3 (en) * | 2004-08-27 | 2006-08-10 | Spherics Inc | Mucoadhesive oral formulations of high permeability, high solubility drugs |
WO2006026556A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Bioadhesive rate-controlled oral dosage formulations |
WO2006026556A3 (en) * | 2004-08-27 | 2006-08-10 | Spherics Inc | Bioadhesive rate-controlled oral dosage formulations |
WO2006026504A2 (en) * | 2004-08-27 | 2006-03-09 | Spherics, Inc. | Mucoadhesive oral formulations of high permeability, high solubility drugs |
WO2007002318A2 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Bioadhesive polymers |
WO2007002318A3 (en) * | 2005-06-23 | 2007-03-29 | Spherics Inc | Bioadhesive polymers |
US20110086095A1 (en) * | 2005-06-23 | 2011-04-14 | Spherics, Inc | Bioadhesive Polymers |
US8491929B2 (en) | 2005-06-23 | 2013-07-23 | Vaunnex Inc. | Bioadhesive polymers |
WO2024078607A1 (en) * | 2022-10-14 | 2024-04-18 | 浙江华海药业股份有限公司 | Pharmaceutical composition for treating parkinson's disease and preparation method therefor |
Also Published As
Publication number | Publication date |
---|---|
GB0111066D0 (en) | 2001-06-27 |
EP1117370A1 (en) | 2001-07-25 |
DE10082749T1 (en) | 2001-11-22 |
AU6142600A (en) | 2001-03-05 |
CA2346291A1 (en) | 2001-02-15 |
GB2384426A (en) | 2003-07-30 |
WO2001010378A3 (en) | 2001-08-30 |
BR9903382A (en) | 2001-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104383554B (en) | For transmitting the polymer based on cyclodextrin of therapeutic agent | |
US6165509A (en) | Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto | |
JPH02300133A (en) | Water-soluble polymerized medical formulation | |
EA010295B1 (en) | Abuse resistant amphetamine compounds | |
JP2003511349A (en) | Poly (dipeptide) as drug carrier | |
US7579020B2 (en) | Controlled release arginine α-ketoglutarate | |
JP2023513249A (en) | Omecamtib mecarbyl formulation | |
EP1030689B1 (en) | Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharmaceutical compositions | |
EP2694079A1 (en) | Polymers and methods for the treatment of pain | |
Kiss et al. | Interaction studies between levodopa and different excipients to develop coground binary mixtures for intranasal application | |
WO2007036946A1 (en) | Compositions for enhanced absorption of biologically active agents | |
EP2042166A1 (en) | Nanocapsules for oral delivery of proteins | |
EP1117370A1 (en) | CONTROLLED RELEASE FROM COPOLYMERS OF ACRYLIC OR METHACRYLIC ACID/L-DOPA, ACRYLIC OR METHACRYLIC ACID/L-$g(a)-METHYL DOPA, ACRYLIC OR METHACRYLIC ACID/CARBIDOPA AND THEIR COMBINATIONS | |
JP2004537566A (en) | Taste masking composition | |
AU6971294A (en) | Process for the preparation of an oral solid dosage form containing diclofenac | |
EP1955710A1 (en) | Aqueous composition comprising chitosan and an acidic drug | |
JP2009531478A (en) | Novel activated poly (ethylene glycol) and related polymers and their applications | |
EP0616813B1 (en) | Antitumor mitoxantrone polymeric compositions | |
US20100093661A1 (en) | Composition comprising chitosan and an acidic drug for oral controlled release | |
EP1693051B1 (en) | Composition containing chitosan for sustained drug release | |
US20220332876A1 (en) | Hydrophilic-hydrophobic copolymer carrying short chain fatty acid ester | |
JP2009525953A (en) | Sustained release formulation of divalproic acid and its derivatives | |
LT et al. | Manufacturing Co. 11710 Naor (JO) | |
US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
WO2023150500A1 (en) | Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase in: |
Ref document number: 0111066 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20000802 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000947704 Country of ref document: EP |
|
ENP | Entry into the national phase in: |
Ref document number: 2346291 Country of ref document: CA Ref document number: 2346291 Country of ref document: CA Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09806671 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000947704 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
RET | De translation (de og part 6b) |
Ref document number: 10082749 Country of ref document: DE Date of ref document: 20011122 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10082749 Country of ref document: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000947704 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |